Skip to main content
. 2022 Sep 24;14:110. doi: 10.1186/s13073-022-01112-z

Table 2.

Clinical characteristics of the replication cohort. Values represent median ± standard deviation

Replication cohort All patients (n=23) Crohn’s disease (n=14) Ulcerative colitis (n=9) Range
Age (y) 37.1 ± 11.9 35.0 ± 12.1 40.8 ± 11.5 18–54
BMI 23.9 ± 4.2 23.9 ± 4.3 24.0 ± 4.4 18.7–32.1
Female sex, n (%) 11 (47.8%) 6 (42.8%) 5 (55.6%)
Time since diagnosis, y 5.0 ± 7 5.8 ± 9 3.8 ± 5 0–28
Smokers, n (%) 7 (30.4%) 7 (50%) 0
Prednisolone >20mg/day, n (%) 6 (26.1%) 4 (28.6%) 2 (22.2%)
Budesonide, n (%) 5 (21.7%) 4 (28.6%) 1 (11.1%)
Thiopurines, n (%) 6 (26.1%) 3 (21.4%) 3 (33.3%)
Mesalamine therapy, n (%) 9 (39.1%) 4 (28.6%) 5 (55.6%)
Clinical remission at week 14, n (%) 8 (57.1%) 3 (33.3%)
Remitters (R)/non-remitters (NR) R NR R NR
C-reactive protein, baseline 5.1±8.25 7.7±19.7 2.4±1.3 8.7±4.5
C-reactive protein, week 2 1.1±2.1 3.3±4.7 1±0.1 3.3±4.7
C-reactive protein, week 6 2.7±3.7 4.2±3.8 2.2±1.9 3.6±4.4
C-reactive protein, week 14 3±4.2 5±3.7 15.5±20.6 4.8±11.9
HBI/pMAYO score, baseline 9±4.1 7.5±2.6 5±0 6±1.6
HBI/pMAYO score, week 2 5±3.0 5.5±0.8 4.5±0.7 5±2.3
HBI/pMAYO score, week 6 2±2.4 6±1.4 2±1.4 5±1.1
HBI/pMAYO score, week 14 0.5±1.5 5±0.9 2±0 6±0.5